Cargando…
Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder
Neuroendocrine carcinoma (NEC) of the gallbladder (GB-NEC) is a rare but extremely malignant subtype of gallbladder cancer (GBC). The genetic and molecular signatures of GB-NEC are poorly understood; thus, molecular targeting is currently unavailable. In the present study, we applied whole-exome seq...
Autores principales: | Liu, Fatao, Li, Yongsheng, Ying, Dongjian, Qiu, Shimei, He, Yong, Li, Maolan, Liu, Yun, Zhang, Yijian, Zhu, Qin, Hu, Yunping, Liu, Liguo, Li, Guoqiang, Pan, Weihua, Jin, Wei, Mu, Jiasheng, Cao, Yang, Liu, Yingbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873252/ https://www.ncbi.nlm.nih.gov/pubmed/33563892 http://dx.doi.org/10.1038/s41392-020-00412-3 |
Ejemplares similares
-
Overview of current targeted therapy in gallbladder cancer
por: Song, Xiaoling, et al.
Publicado: (2020) -
Chloride intracellular channel 1 regulates the antineoplastic effects of metformin in gallbladder cancer cells
por: Liu, Yongchen, et al.
Publicado: (2017) -
The PLGF/c‐MYC/miR‐19a axis promotes metastasis and stemness in gallbladder cancer
por: Li, Huaifeng, et al.
Publicado: (2018) -
TASP1 Promotes Gallbladder Cancer Cell Proliferation and Metastasis by Up-regulating FAM49B via PI3K/AKT Pathway
por: Zhang, Yijian, et al.
Publicado: (2020) -
Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial
por: Yang, Mao, et al.
Publicado: (2023)